Challenging the 50‐50 rule for the basal‐bolus insulin ratio in patients with type 2 diabetes who maintain stable glycaemic control

To assess the rule in real‐world practice, we retrospectively analyzed patients on basal‐bolus therapy that was adjusted at least weekly by an artificial intelligence‐driven titration within the d‐Nav® Insulin Management Technology. The data shows that a 50‐50 ratio of basal‐to‐bolus insulin does not generally apply to patients with T2D who successfully maintain stable glycemia. Therefore, the 50‐50 ratio should not serve as an ongoing treatment guide. Moreover, our results emphasize the importance of at least weekly insulin titrations.